New HPLC Method with Experimental Design and Fluorescence Detection for Analytical Study of Antihypertensive Mixture, Amlodipine and Valsartan

Tadeusz Inglot, Anna Gumieniczek, Paulina Mączka, Ewelina Rutkowska

Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland.

DOI: 10.4236/ajac.2013.41003                

Abstract

New HPLC method was developed for determination of amlodipine and valsartan in their binary mixture as a part of routine control of combined formulations. The method was validated to meet official requirements including selectivity, stability, linearity, precision and accuracy. Chromatography was carried out using a LiChrospher RP-18 column, a mixture containing acetonitrile, phosphate buffer of pH 3.5 and methanol (45:45:10, v/v/v) and new fluorescence detection at 255 nm for excitation and 448 nm for emission. The effect of methanol content, pH of the buffer, flow rate, detection wavelengths and column temperature was estimated in robustness study, according to a plan defined by the Plackett-Burman design. For identification of significant effects, both graphical and statistical methods were used. Ro-bustness for dissolution test was checked estimating the effects of paddle speed, temperature and pH of dissolution medium. The method was proved to complying with all official guidelines. Therefore, it is suitable for determination of amlodipine and valsartan in their binary mixtures for different analytical and pharmaceutical purposes.

Keywords

HPLC Method; Fluorescence Detection; Experimental Design; Amlodipine and Valsartan; Binary Mixture

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	I. Gavras and T. Rosenthal, “Combination Therapy as First-Line Treatment for Hypertension,” Current Hypertension Reports, Vol. 6, No. 4, 2004, pp. 267-272. doi:10.1007/s11906-004-0020-x
[2]	D. Jothieswari, et al., “A validated UV Spectrophotometric Method for the Simultaneous Estimation of Amlodip- ine Besylate, Valsartan and Hydrochlorothiazide in Bulk and in Combined Tablet Dosage Form,” Journal of Pharmaceutical and Biomedical Sciences, Vol. 5, No. 13, 2010, pp. 1-5.
[3]	N. G. Mohamed, “Simultaneous Determination of Amlodipine and Valsartan,” Analytical Chemistry Insights, Vol. 6, No. 1, 2011, pp. 53-59.
[4]	O. M. Abdallah and A. M. Badawey, “Determination of Amlodipine and Valsartan in Binary Mixture Using Derivative Ratio Spectrophotometric, Chemometric and High Performance Liquid Chromatographic UV Methods,” International Journal of Industrial Chemistry, Vol. 2, No. 3, 2011, pp. 131-139.
[5]	D. Kul, B. Dogan-Topal, T. Kutucu, B. Uslu and S. A. Ozkan, “High-Performance Liquid Chromatographic and First Derivative of the Ratio Spectrophotometric Determination of Amlo-dipine and Valsartan in Their Binary mixtures,” Journal of AOAC International, Vol. 93, No. 3, 2010, pp. 882-889.
[6]	R. A. Shaalan and T. S. Belal, “Simultaneous Spectro- fluorimetric Detection of Amlodipine Besylate and Valsartan in Their Combined Tablets,” Drug Testing and Analysis, Vol. 2, No. 10, 2010, pp. 489-493. doi:10.1002/dta.160
[7]	S. R. Dhaneshwar, N. G. Patre and M. V. Maahadik, “Validated TLC Method for Simultaneous Quan-titation of Amlodipine Besylate and Valsartan in Bulk Drug and Formulation,” Chromatographia, Vol. 69, No. 1-2, 2009, pp. 157-161. doi:10.1365/s10337-008-0858-1
[8]	E. S. M. Abu-Nameh, et al., “Simultaneous Determination of Amlodipine Besylate and Valsartan in Tablets by High Performance Liquid Chromatography with UV Detection,” Jordan Journal of Pharmaceutical Sciences, Vol. 4, No. 2, 2011, pp. 105-111.
[9]	S. B. Patel, B. G. Chaudhari, M. K. Buch and A. B. Patel, “Stability Indicating RP-HPLC Method for Simultaneous Determination of Valsartan and Amlodipine from Their Combination Drug Product,” International Journal of ChemTech Research, Vol. 1, No. 4, 2009, pp. 1257-1267.
[10]	M. Celebier, M. S. Kaynak, S. Altinoz and S. Sahin, “HPLC Method Development for the Simultaneous Analysis of Amlodipine and Valsartan in Combined Dosage Forms and in Vitro Dissolution Studies,” Brazilian Journal of Pharmaceutical Sciences, Vol. 46, No. 4, 2010, pp. 761-768.
[11]	K. Anandakumar, D. Jothieswari, R. Subathrai and T. Vetrichelvan, “Validated RP-HPLC Method for the Simultaneous Determination of Amlodipine Besylate, Valsartan, and Hydrochlorothiazide in Combined Pharmaceutical Tablets,” Acta Chromatographica, Vol. 24, No. 1, 2012, pp. 37-50. doi:10.1556/AChrom.24.2012.1.4
[12]	R. A. Shaalan and T. S. Belal, “Gradient HPLC-DAD Determination of the Antihy-pertensive Mixture of Amlodipine Besylate, Valsartan and Hydrochlorothiazide in Combined Pharmaceutical Tablets,” Journal of Liquid Chromatography and Related Technologies, Vol. 35, No. 2, 2012, pp. 215-230. doi:10.1080/10826076.2011.597071
[13]	R. A. Mahske, D. J. Garole, A. A. Mashke and S. Sahasrabudhe, “RP-HPLC Method for Simultaneous Determination of Amlodipine Besylate, Valsartan, Telmisartan, Hydrochlorothiazide and Chlorthalidone: Application to Commercially Available Drug Products,” International Journal of Pharmaceutical Sciences, Vol. 3, No. 1, 2012, pp. 141-149.
[14]	S. E. Vignaduzzo, P. M. Castellano and T. S. Kaufman, “Development and Validation of an HPLC Method for the Simultaneous Determination of Amlodipine, Hydroch- lorothiazide and Valsartan in Tablets of Their Triple Combination and Binary Pharmaceutical Associations,” Journal of Liquid Chromatography and Related Technologies, Vol. 34, No. 19, 2011, pp. 2383-2395. doi:10.1080/10826076.2011.591020
[15]	V. R. Galande, K. G. Baheti and M. H. Dehgan, “Development and Validation of RP-HPLC and HPTLC Method for the Estimation of Valsartan, Hydrochlorothiazide and Amlodipine Besylate in Combined Tablet Dosage Form,” Indian Drugs, Vol. 48, No. 4, 2011, pp. 49-56.
[16]	S. J. Varghese and T. K. Ravi, “Quantitative Simultaneous Determination of Amlodipine, Valsartan and Hydro- chlorothiazide in Exforge HCT Tablets Using High-Performance Liquid Chromatography and High-Performance Thin-Layer Chromatography,” Journal of Liquid Chromatography and Related Technologies, Vol. 34, No. 12, 2011, pp. 981-994. doi:10.1080/10826076.2011.565539
[17]	C. Graffner, “Regulatory Aspects of Drug Dissolution from a European Perspective,” European Journal of Pharmaceutical Sciences, Vol. 29, No. 3-4, 2006, pp. 288-293. doi:10.1016/j.ejps.2006.05.003
[18]	N. Y. Khalil, T. A. Wani, M. A. Abunassif and I. A. Dar- wish, “Sensitive HPLC Method with Fluorescence Detection and On-Line Wavelength Switching for Simultaneous Determination of Valsartan and Amlodipine in Human Plasma,” Journal of Liquid Chromatography and Related Technologies, Vol. 34, No. 20, 2011, pp. 2583-2595. doi:10.1080/10826076.2011.593069
[19]	Y. Vander Heyden, A. Nijhuis, J. Smeyers-Verbeke, B. G. M. Vandeginste and D. L. Massart, “Guidance for Robustness/Ruggedness Tests in Method Validation,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 24, No. 5, 2001, pp. 723-753. doi:10.1016/S0731-7085(00)00529-X